Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients
- 1 August 1997
- journal article
- Published by Elsevier in Kidney International
- Vol. 52 (2) , 517-523
- https://doi.org/10.1038/ki.1997.362
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Hyperhomocysteinemia as a Risk Factor for Cardiovascular Disease in Patients Undergoing HemodialysisPublished by Oxford University Press (OUP) ,2009
- Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patientsAtherosclerosis, 1996
- High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patientsKidney International, 1996
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control studyAtherosclerosis, 1995
- Hyperhomocysteinemia: An Independent Risk Factor for Vascular DiseaseNew England Journal of Medicine, 1991
- Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitusScandinavian Journal of Clinical and Laboratory Investigation, 1991
- Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine‐homocysteine mixed disulphideEuropean Journal of Clinical Investigation, 1979
- Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis.Journal of Clinical Investigation, 1976
- Homocystinuria associated with decreased methylenetetrahydrofolate reductase activityBiochemical and Biophysical Research Communications, 1972